Yüksel, Didem

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14411/6767
Name Variants
Yuksel, Didem
D., Yüksel
Yüksel,D.
Yüksel, Didem
Yuksel,Didem
Y.,Didem
D.,Yuksel
Yuksel,D.
Didem, Yüksel
D.,Yüksel
Y., Didem
Didem, Yuksel
D., Yuksel
Didem Yüksel
Job Title
Doktor Öğretim Üyesi
Email Address
didem.yuksel@atılım.edu.tr
Main Affiliation
Nursing
Status
Website
ORCID ID
0000-0003-2120-7679
Scopus Author ID
57867896700
Turkish CoHE Profile ID
cv
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

14

LIFE BELOW WATER
LIFE BELOW WATER Logo

0

Research Products

2

ZERO HUNGER
ZERO HUNGER Logo

0

Research Products

11

SUSTAINABLE CITIES AND COMMUNITIES
SUSTAINABLE CITIES AND COMMUNITIES Logo

0

Research Products

1

NO POVERTY
NO POVERTY Logo

0

Research Products

12

RESPONSIBLE CONSUMPTION AND PRODUCTION
RESPONSIBLE CONSUMPTION AND PRODUCTION Logo

0

Research Products

7

AFFORDABLE AND CLEAN ENERGY
AFFORDABLE AND CLEAN ENERGY Logo

0

Research Products

5

GENDER EQUALITY
GENDER EQUALITY Logo

0

Research Products

3

GOOD HEALTH AND WELL-BEING
GOOD HEALTH AND WELL-BEING Logo

1

Research Products

9

INDUSTRY, INNOVATION AND INFRASTRUCTURE
INDUSTRY, INNOVATION AND INFRASTRUCTURE Logo

0

Research Products

13

CLIMATE ACTION
CLIMATE ACTION Logo

0

Research Products

6

CLEAN WATER AND SANITATION
CLEAN WATER AND SANITATION Logo

0

Research Products

10

REDUCED INEQUALITIES
REDUCED INEQUALITIES Logo

0

Research Products

4

QUALITY EDUCATION
QUALITY EDUCATION Logo

0

Research Products

15

LIFE ON LAND
LIFE ON LAND Logo

0

Research Products

16

PEACE, JUSTICE AND STRONG INSTITUTIONS
PEACE, JUSTICE AND STRONG INSTITUTIONS Logo

0

Research Products

17

PARTNERSHIPS FOR THE GOALS
PARTNERSHIPS FOR THE GOALS Logo

0

Research Products

8

DECENT WORK AND ECONOMIC GROWTH
DECENT WORK AND ECONOMIC GROWTH Logo

0

Research Products
Documents

1

Citations

7

h-index

1

Go to Scopus profile
This researcher does not have a WoS ID.
Scholarly Output

4

Articles

3

Views / Downloads

8/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

0

Scopus Citation Count

3

WoS h-index

0

Scopus h-index

1

Patents

0

Projects

0

WoS Citations per Publication

0.00

Scopus Citations per Publication

0.75

Open Access Source

0

Supervised Theses

0

Google Analytics Visitor Traffic

JournalCount
Fetal and Pediatric Pathology1
Journal of Pediatric Nursing1
Multiple Sclerosis and Related Disorders1
Neurology Asia1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2024 - 20252
Reset filters

Settings

Author: Yardimci, FigenSubject: Adherence

Scholarly Output Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Challenges Faced by Pediatric Patients With Multiple Sclerosis During Disease Progression and Treatment: A Multicenter Cross-Sectional Study in Turkiye
    (Asean Neurological Assoc, 2025) Yuksel, Didem; Yardimci, Figen
    Background & Objective: Multiple sclerosis is a chronic and progressive disease characterized by inflammation, demyelination and degeneration of the central nervous system. This study aimed to describe the sociodemographic and clinical characteristics of children with multiple sclerosis. Methods: The cross-sectional study was collected data from 120 children who met the research criteria and were under follow-up at 7 hospitals in T & uuml;rkiye between August 2021 and February 2022. Ethical approval was obtained from the Medical Research Ethics Committee of Ege University. The researchers developed the "The Sociodemographic Form "used in the study by based on a comprehensive literature review and previous research experiences. The form was used according to expert opinion. Results: The study included 120 eligible patients, of whom 71.2% were girls. The mean age (+/- SD) at disease onset was 13.6 +/- 2.2 years, while the mean age at the time of the study was 15.7 +/- 1.5 years. Most of the participants were high school students (84.2%), and 53.3% resided in metropolitan areas. All participants were receiving disease-modifying therapy. The study found that 67.5% of the children had school absenteeism due to the disease. Furthermore, 75% of the children experienced supratentorial symptoms, with 50% presented with optic symptoms, and 37.5% exhibiting brainstem symptoms prior to diagnosis. Drug-related side effects were reported in 58.3% of children. Additionally,99.2% of the children received information about the disease. Furthermore, 75% of the children experienced challenges during the disease and treatment process. Among these children who encountered difficulties, 52.5% reported psychological problems, 42.5% experienced side effects due to medication, 42.5% had difficulty accessing accurate and sufficient information about disease and treatment management, 32.5% encountered social and school-related issues, and 5.8% had concerns related to the clinical environment. Conclusion: Childhood multiple sclerosis is more prevalent among girls, particularly in the relapsing-remitting form. The most commonly used treatments for pediatric multiple sclerosis include interferon beta-1a and glatiramer acetate. The findings of this study indicate that a significant proportion of participating children encountered challenges during the disease and treatment process, with more than half experiencing drug-related side effects. These challenges underscore the potential negative impact on treatment adherence in this population.
  • Thumbnail Image
    Article
    Development and Psychometric Evaluation of the Treatment Management Adherence Scale for Children With Multiple Sclerosis
    (Elsevier Sci Ltd, 2024) Yuksel, Didem; Yardimci, Figen
    Background: Pediatric multiple sclerosis (pMS) is a chronic inflammatory, demyelinating, and neurodegenerative disease affecting the central nervous system in children and adolescents The aim of this correlational, comparative study was to develop an assessment scale for adherence to treatment management in pMS. Methods: Two measurement tools were used to develop a scientifically sound tool to assess adherence in pediatric patients (12-18 years) diagnosed with multiple sclerosis (MS). Cases of pMS (n = 120) in 7 hospitals in Turkey were included between August 2021-February 2022. The tools were a "Sociodemographic and Disease-Related Information" and a newly developed "Treatment Management Adherence Scale for Children with Multiple Sclerosis". The form and questionnaire were completed by the children through online using the Zoom platform in approximately 10 min. The questionnaire on adherence contains 16 items related to the disease and treatment, scored in a 5-point Likert type. Face validity was established by pretesting with 20 children, and construct validity was established using the statistical methods of exploratory factor analysis and confirmatory factor analysis. For the reliability of the scale, Cronbach's Alpha and omega coefficients, item test correlation values, split-half, test-retest techniques were used. Results: There were 120 eligible patients, 71.2 % girls, with mean age (fSD) 13,6 f 2,2 years at disease onset and 15,7 f 1,5 at the time of the study, all under disease-modifying therapy. The sample size and items were sufficient to conduct a factor analysis. The Cronbach's Alpha and Omega value was 0.75, indicating participants' opinions were consistent across items. The mean content validity index was 0.93, showing the scale represented the measured data, and the exploratory factor analysis showed the scale measures adherence in 55 % of patients (desired figures: >0.80 and 40-60 % respectively). The 16 items of the questionnaire were grouped into 4 dimensions. These dimensions were termed 'physiological', 'self-concept', 'role function' and 'interdependence', in line with different styles of adaptation. The total score can be between 16 and 80, with higher scores indicating strong adherence to treatment. The mean total score of 54,3 f 9,53 (min=31, max= 75) in this study was in the "moderate adherence" range. Conclusions: This new scale is the first to assess adherence in pMS. The study supports its validity, reliability, and likelihood to address adjustment issues in children and adolescents with MS accurately and can be recommended for clinical use.